Media.Player

Neuraminidase Inhibition to Improve Glycocalyx Volume and Function to Ameliorate Cardiovascular Diseases in Pathologies Associated with Glycocalyx Damage

Detailed Technology Description

None

Others

*Abstract

University of MissouriOffice of Technology Management & Industry RelationsNon-Confidential Abstract of InventionUM Disclosure No. 17UMC103Treatment of Cardiovascular Disease Targeting Improved Glycocalyx Volume and Function INNOVATION:This new technology is a therapeutic (and preventative) for cardiovascular disease. The invention described herein inhibits an enzyme involved in the degradation of the endothelial glycocalyx, thus improving glycocalyx volume and function, and resulting in normalization of nitric oxide levels in the blood, and reduction of risk for development of cardiovascular disease. Studies have shown a significant effects in a mouse model, including target enzyme inhibition and a dramatic improvement of arterial flow-mediated dilation in response to shear stress. BACKGROUND:The glycocalyx is a thin layer of glycoproteins and proteoglycans interwoven forming a luminal mesh that separates the endothelial cell membrane from the blood that flows within the vasculature. Primary functions of the glycocalyx include mechanotransduction of shear stress and semi-permeability to tangential flow of blood and components thereof. Certain circulating enzymes can affect the glycocalyx layer by cleaving specific moieties on the surface. Glycocalyx degradation leads to attenuation of flow-mediated dilation and increased permeability. Attenuation of flow-mediated dilation is attributed to decreased production of nitric oxide. Increased permeability is attributed to degraded crosslinks between the glycocalyx. This compromised glycocalyx is seen in patients with type II diabetes, coronary artery disease, peripheral vascular disease, cerebrovascular disease, atherosclerosis, and hypertension.APPLICATIONS:• Cardiovascular disease treatment and prevention• Type II diabetes-related cardiovascular disease prevention• Other cardiovascular diseasesADVANTAGES:• Novel therapeutic and preventative of cardiovascular disease• Repurposed FDA approved drug • Improved flow-mediated dilation in isolated femoral arteries • Improved femoral artery endothelium-dependent acetylcholine-induced vasodilation PATENT STATUS:• Patent PendingLICENSING POTENTIAL:• University seeks licensee with the potential to commercializeINVENTOR(S):• Luis Martinez-Lemus• Christopher FootePUBLICATIONS:• In processCONTACT INFO: Office of Technology Management & Industry Relations Brian Buntaine, MS, MBA Senior Licensing & Business Development Associate Email: buntaineb@missouri.edu Phone: 573-882-0470

*Principal Investigator

Name: Luis Martinez-Lemus, Assistan Professor in Medical Pharmacology

Department:

Name: Christopher Foote, Sr. Research Specialist

Department:

Country/Region

USA